New York State Teachers Retirement System Acquires 2,332 Shares of Amgen Inc. $AMGN

Posted by Stanley Muller on Jul 3rd, 2026

New York State Teachers Retirement System increased its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 441,342 shares of the medical research company’s stock after acquiring an additional 2,332 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Amgen worth $155,286,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Optas LLC boosted its stake in Amgen by 23.9% during the first quarter. Optas LLC now owns 1,886 shares of the medical research company’s stock worth $664,000 after buying an additional 364 shares during the period. MOR Wealth Management LLC bought a new position in Amgen during the first quarter valued at $299,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Amgen in the first quarter valued at $11,400,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Amgen by 59.9% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 166,082 shares of the medical research company’s stock worth $58,436,000 after acquiring an additional 62,190 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC lifted its holdings in shares of Amgen by 91.9% in the 1st quarter. Elevation Point Wealth Partners LLC now owns 21,443 shares of the medical research company’s stock worth $7,545,000 after acquiring an additional 10,271 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: A federal judge blocked Colorado’s attempt to cap the price of Amgen’s Enbrel, removing a potentially precedent-setting state-level pricing threat for one of Amgen’s most important legacy drugs. Article: Judge blocks Colorado’s first-of-its-kind price cap on Amgen’s Enbrel
Positive Sentiment: Amgen continues to advance its pipeline, with updates on Rocatinlimab in asthma, evolocumab bioavailability, and AMG 133 in obesity, reinforcing the company’s long-term growth story. Article: Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line Article: Amgen Refines Its PCSK9 Franchise with New Evolocumab Bioavailability Study Article: Amgen’s AMG 133 Trial Adds a New Data Point in the Obesity Drug Race
Positive Sentiment: Analysts at Mizuho highlighted Amgen’s pipeline potential, especially MariTide and olpasiran, and raised their price target, signaling continued Street confidence in the company’s future growth prospects. Article: Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran
Neutral Sentiment: Roche reported positive late-stage lung cancer data for divarasib versus drugs sold by Amgen and Bristol Myers, which adds competitive pressure in the oncology market but does not change Amgen’s fundamentals by itself. Article: Roche KRAS drug succeeds in head-to-head lung cancer study
Negative Sentiment: A medical journal retracted a pivotal Tavneos paper, which could add to regulatory scrutiny around the drug and weigh on sentiment toward Amgen’s portfolio. Article: Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 3.5%

Shares of Amgen stock opened at $374.15 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a market cap of $201.93 billion, a price-to-earnings ratio of 26.04, a PEG ratio of 3.56 and a beta of 0.41. The firm’s 50-day moving average is $341.87 and its two-hundred day moving average is $347.74. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the previous year, the business posted $4.90 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts expect that Amgen Inc. will post 22.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on AMGN. Truist Financial upped their price target on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a report on Friday, May 1st. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Argus decreased their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 target price on shares of Amgen in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $355.50.

Get Our Latest Research Report on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.